{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=7", "query": { "intervention": "ipilimumab", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 640, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T13:18:36.517Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02823574", "title": "Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 425, "start_date": "2016-11-08", "completion_date": "2022-04-21", "has_results": true, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 28, "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02823574" }, { "nct_id": "NCT05501665", "title": "Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage III Lung Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan", "type": "OTHER" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-05-09", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05501665" }, { "nct_id": "NCT03215706", "title": "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 719, "start_date": "2017-08-24", "completion_date": "2024-10-18", "has_results": true, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 16, "location_summary": "Colorado Springs, Colorado • Plainville, Connecticut • Jacksonville, Florida + 12 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Plainville", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03215706" }, { "nct_id": "NCT01729806", "title": "Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD20 Positive", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2012-11-19", "completion_date": "2018-03-30", "has_results": false, "last_update_posted_date": "2018-04-11", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729806" }, { "nct_id": "NCT04899921", "title": "Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Troriluzole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-06-30", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04899921" }, { "nct_id": "NCT04511013", "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-01-06", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 331, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 234 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511013" }, { "nct_id": "NCT02488759", "title": "An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-10-13", "completion_date": "2022-10-24", "has_results": true, "last_update_posted_date": "2023-11-13", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 14, "location_summary": "Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lutherville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02488759" }, { "nct_id": "NCT02714218", "title": "A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Nivolumab 3 mg/kg IV", "type": "BIOLOGICAL" }, { "name": "Ipilimumab 1 mg/kg IV", "type": "BIOLOGICAL" }, { "name": "Nivolumab 1 mg/kg IV", "type": "BIOLOGICAL" }, { "name": "Ipilimumab 3 mg/kg IV", "type": "BIOLOGICAL" }, { "name": "Nivolumab 6 mg/kg IV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 387, "start_date": "2016-04-04", "completion_date": "2021-05-28", "has_results": true, "last_update_posted_date": "2022-06-24", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 11, "location_summary": "Aurora, Colorado • Tampa, Florida • Fridley, Minnesota + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fridley", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02714218" }, { "nct_id": "NCT01497808", "title": "RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-11-29", "completion_date": "2015-10-12", "has_results": true, "last_update_posted_date": "2021-08-10", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497808" }, { "nct_id": "NCT03865082", "title": "Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Tilsotolimod", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idera Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-10-29", "completion_date": "2022-04", "has_results": false, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-10-24T13:18:36.517Z", "location_count": 3, "location_summary": "Tucson, Arizona • Newport Beach, California • Houston, Texas", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03865082" } ] }